RxDoctor Payments Data

Patricia Coleman, MD

Internal Medicine · Eastpointe, MINPI 1770546103

Payments from drug & device makers

$1,079in general payments, 2019–2025

Across 95 payments — averaging $11.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$507
  • Astellas Pharma US Inc$67
  • Novo Nordisk$58
  • Pfizer$58
  • Novartis$52
  • Lilly USA, LLC$42
  • plus $296 from 12 others

What the payments were for

  • Food & beverage$1,079100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,079 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$17,522
Medicare patients
103
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide30$34,431
TrulicityDulaglutide12$29,561
OzempicSemaglutide21$28,226
JardianceEmpagliflozin21$25,316
EliquisApixaban17$21,036
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,911
MyrbetriqMirabegron11$9,324
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,614
Albuterol Sulfate HfaAlbuterol Sulfate65$2,390
Lidocaine18$1,596
Ventolin HfaAlbuterol Sulfate24$1,417
Losartan Potassium76$959
Atorvastatin Calcium71$950
Gabapentin64$897
Duloxetine Hcl33$641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$42$63,99242 claims
Novo NordiskOzempic$58$28,22621 claims
Boehringer IngelheimJardiance$28$25,31621 claims
PfizerEliquis$58$21,03617 claims
GSKTrelegy Ellipta$29$14,91114 claims
Astellas Pharma US IncMyrbetriq$67$9,32411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Eastpointe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →